États-Unis · Bourse & Finance · The Motley Fool

Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield

Publié par The Motley Fool · États-Unis il y a 8 h

As it stands, roughly one-third of Pfizer's revenue is subject to patent expirations over the next couple of years. It's nothing to dismiss. Largely lost in the matter, however,…

Lire l'article complet sur The Motley Fool Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.fool.com)

Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield

À lire aussi

'Uptober' Starts Green as Bitcoin ETFs Draw $134 Million

Private Equity Firms Double Down on Fossil Fuels

American Airlines adds cash-and-miles bookings as loyalty battle heats up

Gen Z is poised to be wealthier than millennials but despair over economy — ‘they get spammed and scammed, and there are tons of fake jobs out there’

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

This NYC startup requires 4 days in office but just let everyone work remote for a whole month

Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield

Partager

À lire aussi

'Uptober' Starts Green as Bitcoin ETFs Draw $134 Million

Private Equity Firms Double Down on Fossil Fuels

American Airlines adds cash-and-miles bookings as loyalty battle heats up

Gen Z is poised to be wealthier than millennials but despair over economy — ‘they get spammed and scammed, and there are tons of fake jobs out there’

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

This NYC startup requires 4 days in office but just let everyone work remote for a whole month